JKOM Cloud Health Technology Co.

JKOM functions as a hybrid investment and operating platform focused on cloud-based health IT. The firm invests in digital-health and AI companies, primarily in the U.S., and then acts as the distribution and localization partner for those technologies inside Chinese public hospitals. This operational layer generates revenue through software licensing and implementation contracts with provincial health bureaus, making JKOM more of an operating company than a pure fund.

JKOM sources through its clinical and engineering networks in both Silicon Valley and Jiangsu province. The firm appears to target companies whose products can be adapted for China's hospital IT environment—particularly FHIR-compliant platforms, AI diagnostic modules, and cloud PACS systems. Its deal flow likely depends on relationships with health-tech accelerators, academic medical centers, and the Israeli digital-health ecosystem, though sourcing specifics are not publicly detailed.

No. JKOM does not appear to operate a fund structure with limited partners, a stated fund life, or a conventional fee-and-carry model. Its operating-company posture is evidenced by direct technology-implementation contracts with Chinese hospital groups, generating revenue independent of portfolio company exits. This blurs the line between asset manager and technology vendor.

Investment activity concentrates on U.S. and Israeli health-AI startups. Operational deployment is focused on China's eastern provinces, particularly Jiangsu, where the firm has been named in government health-commission minutes as a technology partner for hospital digitization projects in cities such as Nanjing and Suzhou.

Based on its cross-border operating model, JKOM likely targets early- to growth-stage companies whose technology is mature enough for clinical deployment but still requires localization and distribution support. The firm's structure allows it to act as a venture investor and a de facto international commercial partner simultaneously, which is most valuable to companies at the Series A through C stage seeking China market entry.